US5773001A
(en)
*
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5714586A
(en)
*
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
*
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
WO1999039207A1
(en)
*
|
1998-01-29 |
1999-08-05 |
Pharmacopeia, Inc. |
Acid cleavable phenoxyalkyl linker for combinatorial synthesis
|
US6008321A
(en)
*
|
1998-03-16 |
1999-12-28 |
Pharmacopeia, Inc. |
Universal linker for combinatorial synthesis
|
US6914130B2
(en)
*
|
1998-06-17 |
2005-07-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US6733998B1
(en)
|
1998-12-07 |
2004-05-11 |
Sloan-Kettering Institute For Cancer Research |
Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
|
US20050159591A1
(en)
*
|
1999-06-02 |
2005-07-21 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
KR100850389B1
(ko)
|
1999-06-25 |
2008-08-04 |
제넨테크, 인크. |
인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법
|
US20040001827A1
(en)
*
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
EP1240337B1
(en)
*
|
1999-12-24 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
US20060228364A1
(en)
*
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
AU2001233027A1
(en)
*
|
2000-01-27 |
2001-08-07 |
Genetics Institute, Llc |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
IL155726A0
(en)
|
2000-12-28 |
2003-11-23 |
Wyeth Corp |
Recombinant protective protein from streptococcus pneumoniae
|
US6652853B2
(en)
*
|
2001-03-08 |
2003-11-25 |
Ludwig Institute For Cancer Research |
Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
|
NZ511705A
(en)
*
|
2001-05-14 |
2004-03-26 |
Horticulture & Food Res Inst |
Methods and rapid immunoassay device for detecting progesterone and other steroids
|
CA2448319C
(en)
*
|
2001-05-31 |
2010-07-27 |
Medarex, Inc. |
Cytotoxins, prodrugs, linkers and stabilizers useful therefor
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
EP2000545B1
(en)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of lung tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040086504A1
(en)
*
|
2001-06-21 |
2004-05-06 |
Deepak Sampath |
Cyr61 as a target for treatment and diagnosis of breast cancer
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
EP1487877B1
(en)
|
2001-09-18 |
2010-10-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis of tumors
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
KR20080106369A
(ko)
|
2002-01-02 |
2008-12-04 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
JP2005536190A
(ja)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
DK2371392T3
(en)
|
2002-05-02 |
2015-08-31 |
Wyeth Holdings Llc |
Calicheamicin derivative / carrier conjugates
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
KR100960560B1
(ko)
|
2002-09-27 |
2010-06-03 |
젠코어 인코포레이티드 |
최적화된 Fc 변이체 및 그의 제조 방법
|
NZ563328A
(en)
|
2002-10-16 |
2009-08-28 |
Euro Celtique Sa |
Antibodies that bind cell-associated CA 125/0772P and methods of use thereof
|
US20040152632A1
(en)
*
|
2002-11-06 |
2004-08-05 |
Wyeth |
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
PT1641822E
(pt)
|
2003-07-08 |
2013-08-27 |
Genentech Inc |
Polipéptidos heterólogos il-17 a/f e suas utilizações terapêuticas
|
NZ544756A
(en)
|
2003-07-22 |
2009-09-25 |
Astex Therapeutics Ltd |
3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
EP1660519B1
(en)
*
|
2003-07-29 |
2014-05-14 |
Immunomedics, Inc. |
Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule
|
JP2007501011A
(ja)
*
|
2003-08-01 |
2007-01-25 |
ジェネンテック・インコーポレーテッド |
制限多様性配列を有する結合型ポリペプチド
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US20050282168A1
(en)
*
|
2003-09-29 |
2005-12-22 |
Wyeth |
Cell surface molecules as markers and therapeutic agents against kidney cancers
|
ES2697327T3
(es)
|
2003-11-06 |
2019-01-23 |
Seattle Genetics Inc |
Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
|
DE602004024921D1
(de)
|
2003-11-17 |
2010-02-11 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
MXPA06006985A
(es)
|
2003-12-19 |
2006-08-31 |
Genentech Inc |
Fragmentos de anticuerpo monovalente utiles como terapueticos.
|
AR048098A1
(es)
*
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
US7527791B2
(en)
|
2004-03-31 |
2009-05-05 |
Genentech, Inc. |
Humanized anti-TGF-beta antibodies
|
ES2549077T3
(es)
*
|
2004-04-07 |
2015-10-22 |
Genentech, Inc. |
Espectrometría de masas de conjugados de anticuerpos
|
MXPA06013413A
(es)
*
|
2004-05-19 |
2007-01-23 |
Medarex Inc |
Enlazadores quimicos y conjugados de los mismos.
|
RU2402548C2
(ru)
*
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
EP2940043A1
(en)
|
2004-07-15 |
2015-11-04 |
Xencor, Inc. |
Optimized fc variants
|
CN102641503A
(zh)
|
2004-07-20 |
2012-08-22 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂,组合,以及其用途
|
JP5226308B2
(ja)
|
2004-07-26 |
2013-07-03 |
ジェネンテック, インコーポレイテッド |
肝細胞増殖因子活性化を制御するための方法及び組成物
|
AU2004224925C1
(en)
*
|
2004-08-30 |
2011-07-21 |
Biotest Ag |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
DK1784426T3
(da)
*
|
2004-09-03 |
2012-03-12 |
Genentech Inc |
Humaniserede anti-beta7-antagonister og anvendelser deraf
|
BRPI0515113A
(pt)
*
|
2004-09-10 |
2008-07-01 |
Wyeth Corp |
anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
US20060073152A1
(en)
*
|
2004-10-05 |
2006-04-06 |
Genentech, Inc. |
Therapeutic agents with decreased toxicity
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP1817340B1
(en)
|
2004-11-12 |
2012-05-16 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP1817059A2
(en)
|
2004-12-01 |
2007-08-15 |
Genentech, Inc. |
Conjugates of 1,8-bis-naphthalimides with an antibody
|
ES2343746T3
(es)
|
2005-01-07 |
2010-08-09 |
Diadexus, Inc. |
Composiciones de anticuerpo ovr110 y metodos de uso.
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
CN101124249B
(zh)
*
|
2005-02-18 |
2011-06-29 |
米德列斯公司 |
抗前列腺特异性膜抗原(psma)的人单克隆抗体
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
CA2604844A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics, Inc. |
Cancer-related genes
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
EP2186402A1
(en)
|
2005-06-06 |
2010-05-19 |
Genentech, Inc. |
Knock-out animal models for novel genes and methods of use
|
US20070003559A1
(en)
*
|
2005-07-01 |
2007-01-04 |
Wyeth |
Methods of determining pharmacokinetics of targeted therapies
|
EP2004695A2
(en)
|
2005-07-08 |
2008-12-24 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
AU2006297126A1
(en)
|
2005-09-30 |
2007-04-12 |
Government Of The United States Of America, As Represented By The Secretary |
Methods and compositions for modulating immune tolerance
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
US7847105B2
(en)
|
2005-10-26 |
2010-12-07 |
Medarex, Inc. |
Methods and compounds for preparing CC-1065 analogs
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
EP1957540B1
(en)
*
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
EP1954719A2
(en)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
US20070160577A1
(en)
*
|
2005-12-06 |
2007-07-12 |
Wyeth |
Interleukin-11 compositions and methods of use
|
EP2325208B1
(en)
|
2005-12-15 |
2017-09-20 |
Genentech, Inc. |
Polyubiquitin antibodies
|
EP1973950B1
(en)
|
2006-01-05 |
2014-09-17 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using the same
|
AU2007233263A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
AU2012261705B2
(en)
*
|
2006-02-21 |
2014-02-06 |
Wyeth Llc |
Processes for the convergent synthesis of calicheamicin derivatives
|
AU2014202414B2
(en)
*
|
2006-02-21 |
2016-06-02 |
Wyeth Llc |
Processes for the convergent synthesis of calicheamicin derivatives
|
TW200806685A
(en)
*
|
2006-02-21 |
2008-02-01 |
Wyeth Corp |
Processes for the convergent synthesis of calicheamicin derivatives
|
CA2644743C
(en)
|
2006-03-08 |
2015-05-19 |
Waldemar Debinski |
Soluble monomeric ephrin a1
|
PL1994055T3
(pl)
|
2006-03-10 |
2015-02-27 |
Wyeth Llc |
Przeciwciała anty-5T4 i ich zastosowanie
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
WO2007109376A2
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
EP2407483A1
(en)
|
2006-04-13 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancers
|
EP2010662A2
(en)
|
2006-04-19 |
2009-01-07 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007134132A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
SI2383297T1
(sl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc. |
Optimizirana antitelesa, ki ciljajo cd19
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
DK2845866T3
(en)
|
2006-10-27 |
2017-07-10 |
Genentech Inc |
Antibodies and immunoconjugates and their applications
|
AU2007325283B2
(en)
|
2006-11-27 |
2012-08-30 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
WO2008103693A2
(en)
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
EP2899541A1
(en)
*
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
EP2474556A3
(en)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1 inhibitors for treating, diagnosing or detecting cancer
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
PT2155248E
(pt)
|
2007-04-12 |
2015-10-23 |
Brigham & Womens Hospital |
Direcionamento a abcb5 para tratameto do cancro
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
DK2176296T3
(da)
|
2007-07-16 |
2012-05-21 |
Genentech Inc |
Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
ES2502217T3
(es)
|
2007-10-02 |
2014-10-03 |
Genentech, Inc. |
Antagonistas de NLRR-1 y sus usos
|
CN102089324B
(zh)
|
2007-11-12 |
2014-04-16 |
特罗科隆科学有限公司 |
用于对流行性感冒进行治疗以及诊断的组合物以及方法
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
AU2008339913B2
(en)
*
|
2007-12-26 |
2014-03-20 |
Biotest Ag |
Methods and agents for improving targeting of CD138 expressing tumor cells
|
US9011864B2
(en)
*
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
CN105418762B
(zh)
|
2007-12-26 |
2019-11-05 |
Xencor公司 |
与FcRn结合改变的Fc变体
|
CN101965366B
(zh)
*
|
2007-12-26 |
2016-04-27 |
生物测试股份公司 |
靶向cd138的免疫缀合物及其应用
|
WO2009080829A1
(en)
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MX351557B
(es)
|
2008-01-31 |
2017-10-19 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
|
CN102015766B
(zh)
|
2008-03-10 |
2014-07-16 |
特罗科隆科学有限公司 |
用于对巨细胞病毒感染进行治疗以及诊断的组合物以及方法
|
US20110123530A1
(en)
*
|
2008-03-31 |
2011-05-26 |
Arron Joseph R |
Compositions and methods for treating and diagnosing asthma
|
EP3605088A1
(en)
|
2008-04-09 |
2020-02-05 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
MX2010012368A
(es)
*
|
2008-05-16 |
2010-12-06 |
Genentech Inc |
Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
WO2010011347A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
AU2009298569A1
(en)
|
2008-10-01 |
2010-04-08 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
CA2747248A1
(en)
|
2008-12-17 |
2010-07-15 |
Sharookh Kapadia |
Hepatitis c virus combination therapy
|
EP2396347B1
(en)
|
2009-02-11 |
2017-04-12 |
Albumedix A/S |
Albumin variants and conjugates
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
CA2755640C
(en)
|
2009-03-20 |
2018-05-22 |
Genentech, Inc. |
Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
|
KR101830024B1
(ko)
|
2009-03-25 |
2018-02-19 |
제넨테크, 인크. |
항-fgfr3 항체 및 그의 사용 방법
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗-α5β1抗體及其用途
|
AU2010236787A1
(en)
|
2009-04-01 |
2011-11-10 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
AU2010236256C1
(en)
|
2009-04-16 |
2015-10-22 |
Abbvie Biotherapeutics Inc. |
Anti-TNF-alpha antibodies and their uses
|
US9296785B2
(en)
|
2009-04-17 |
2016-03-29 |
Wake Forest University Health Sciences |
IL-13 receptor binding peptides
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
WO2010126551A1
(en)
|
2009-04-30 |
2010-11-04 |
Immunogen, Inc. |
Potent conjugates and hydrophilic linkers
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
ES2643446T3
(es)
|
2009-06-04 |
2017-11-22 |
Novartis Ag |
Métodos para la identificación de sitios para conjugación de IgG
|
JP5785941B2
(ja)
|
2009-06-17 |
2015-09-30 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗vegf抗体とその使用
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
HUE026447T2
(en)
|
2009-10-16 |
2016-05-30 |
Novartis Ag |
Pharmacodynamic tumor response biomarkers
|
WO2011049868A1
(en)
*
|
2009-10-19 |
2011-04-28 |
Genentech, Inc. |
Modulators of hepatocyte growth factor activator
|
ES2534646T3
(es)
|
2009-10-22 |
2015-04-27 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-hepsina y métodos de uso de los mismos
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011059762A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
BR112012009450A2
(pt)
|
2009-10-30 |
2017-05-23 |
Novozymes Biopharma Dk As |
variantes de albumina
|
WO2011057120A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
EP3778917A3
(en)
|
2009-12-04 |
2021-06-09 |
F. Hoffmann-La Roche AG |
Multispecific antibodies, antibody analogs, compositions, and methods
|
MY159679A
(en)
*
|
2009-12-10 |
2017-01-13 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
SG181905A1
(en)
|
2009-12-23 |
2012-07-30 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
EA027502B1
(ru)
|
2009-12-23 |
2017-08-31 |
Зиниммуне Гмбх |
Антитела против flt3 и способы их применения
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
DK2531206T3
(en)
|
2010-02-04 |
2017-09-11 |
Morphotek Inc |
CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USE THEREOF
|
JP6046494B2
(ja)
|
2010-02-08 |
2016-12-14 |
アジェンシス,インコーポレイテッド |
161p2f10bタンパク質に結合する抗体薬物コンジュゲート(adc)
|
CA2784211C
(en)
|
2010-02-18 |
2019-12-24 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
TWI429453B
(zh)
|
2010-02-23 |
2014-03-11 |
Genentech Inc |
抗tat419抗體及其用途
|
US9221910B2
(en)
|
2010-03-05 |
2015-12-29 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
MX2012010014A
(es)
|
2010-03-05 |
2012-09-21 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
CN102822198B
(zh)
|
2010-03-12 |
2016-08-31 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
TW201138823A
(en)
|
2010-03-24 |
2011-11-16 |
Genentech Inc |
Anti-LRP6 antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
EP2556087A1
(en)
|
2010-04-09 |
2013-02-13 |
Novozymes Biopharma DK A/S |
Albumin derivatives and variants
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
MX336540B
(es)
|
2010-06-08 |
2016-01-22 |
Genentech Inc |
Conjugados y anticuerpos manipulados geneticamente con cisteina.
|
CA2794731C
(en)
|
2010-06-18 |
2019-03-19 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
Hoffmann La Roche |
biomarcadores de leucemia linfocítica crônica (cll)
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
JP5841149B2
(ja)
|
2010-08-13 |
2016-01-13 |
ロシュ グリクアート アーゲー |
抗テネイシンca2抗体及び使用の方法
|
MX358859B
(es)
|
2010-08-13 |
2018-09-05 |
Roche Glycart Ag |
Anticuerpos anti-fap y métodos de utilización.
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
JP2013537966A
(ja)
|
2010-08-31 |
2013-10-07 |
ジェネンテック, インコーポレイテッド |
バイオマーカー及び治療の方法
|
PL3556396T3
(pl)
|
2010-08-31 |
2022-09-12 |
Theraclone Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
|
US9085621B2
(en)
|
2010-09-10 |
2015-07-21 |
Apexigen, Inc. |
Anti-IL-1β antibodies
|
EP2621526B1
(en)
|
2010-09-29 |
2018-06-06 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP6163429B2
(ja)
|
2010-11-10 |
2017-07-12 |
ジェネンテック, インコーポレイテッド |
神経疾患免疫治療のための方法及び組成物
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
KR101923282B1
(ko)
|
2010-12-16 |
2018-11-28 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
WO2012088313A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
EP2673297A2
(en)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
JP2014506580A
(ja)
|
2011-02-14 |
2014-03-17 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
CA2827581A1
(en)
|
2011-03-03 |
2012-09-07 |
Apexigen, Inc. |
Anti-il-6 receptor antibodies and methods of use
|
WO2012122513A2
(en)
|
2011-03-10 |
2012-09-13 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
BR112013023576A2
(pt)
|
2011-03-15 |
2016-12-06 |
Theraclone Sciences Inc |
composições e métodos para a terapia e diagnóstico de influenza
|
DK3138581T3
(en)
|
2011-03-17 |
2019-04-15 |
Univ Birmingham |
REDIRECTED IMMUNTERY
|
CN105949313B
(zh)
|
2011-03-29 |
2021-06-15 |
罗切格利卡特公司 |
抗体Fc变体
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
RU2609647C2
(ru)
|
2011-04-29 |
2017-02-02 |
Апексиджен, Инк. |
Анти-cd40-антитела и способы применения
|
SG194917A1
(en)
|
2011-05-16 |
2013-12-30 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
CN106279418A
(zh)
|
2011-05-27 |
2017-01-04 |
葛兰素集团有限公司 |
Bcma(cd269/tnfrsf17)结合蛋白
|
BR112013031819B1
(pt)
|
2011-06-10 |
2022-05-03 |
Mersana Therapeutics, Inc |
Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
|
WO2013003507A1
(en)
|
2011-06-27 |
2013-01-03 |
Morphotek, Inc. |
Multifunctional agents
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
AU2012295394B2
(en)
|
2011-08-12 |
2016-04-14 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
CA2844540C
(en)
|
2011-08-23 |
2018-10-16 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
BR112014004166A2
(pt)
|
2011-08-23 |
2018-05-29 |
Roche Glycart Ag |
anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
EP2758055A1
(en)
|
2011-09-19 |
2014-07-30 |
F.Hoffmann-La Roche Ag |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
RU2014114119A
(ru)
|
2011-09-23 |
2015-10-27 |
Рош Гликарт Аг |
Биспецифические анти-egfr/анти igf-1r-антитела
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
JP6310394B2
(ja)
|
2011-10-10 |
2018-04-11 |
ゼンコア インコーポレイテッド |
抗体を精製する方法
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
JP6532678B2
(ja)
|
2011-10-14 |
2019-06-19 |
ジェネンテック, インコーポレイテッド |
抗HtrA1抗体及び使用方法
|
WO2013056054A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc |
Peptide inhibitors of bace1
|
BR112014008590A2
(pt)
|
2011-10-15 |
2017-10-24 |
Genentech Inc |
métodos de uso de antagonistas de scd1
|
US20140308204A1
(en)
|
2011-10-25 |
2014-10-16 |
Memorial Sloan Kettering Cancer Center |
Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
BR112014010774A2
(pt)
|
2011-11-02 |
2017-06-13 |
Apexigen Inc |
anticorpos anti-kdr e métodos de uso
|
EP2589609A1
(en)
|
2011-11-03 |
2013-05-08 |
Pierre Fabre Medicament |
Antigen binding protein and its use as addressing product for the treatment of cancer
|
WO2013075066A2
(en)
|
2011-11-18 |
2013-05-23 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
US10117932B2
(en)
|
2011-12-08 |
2018-11-06 |
Biotest Ag |
Uses of immunoconjugates targeting CD138
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
EP2793941A1
(en)
|
2011-12-23 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Articles of manufacture and methods for co-administration of antibodies
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
JP6242813B2
(ja)
|
2012-01-18 |
2017-12-06 |
ジェネンテック, インコーポレイテッド |
抗lrp5抗体及び使用方法
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
US9567642B2
(en)
|
2012-02-02 |
2017-02-14 |
Massachusetts Institute Of Technology |
Methods and products related to targeted cancer therapy
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
AU2013216753B2
(en)
|
2012-02-11 |
2017-09-21 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
KR102069397B1
(ko)
|
2012-02-15 |
2020-01-22 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 기재 친화성 크로마토그래피
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
WO2013135896A1
(en)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
US10024860B2
(en)
|
2012-03-28 |
2018-07-17 |
Massachusetts Institute Of Technology |
Cancer-related extracellular matrix signatures and related methods and products
|
US9526800B2
(en)
|
2012-03-28 |
2016-12-27 |
Massachusetts Institute Of Technology |
Cancer-related extracellular matrix signatures and related methods and products
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
RU2015101113A
(ru)
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Fc-영역 접합체의 제조 방법 및 그의 용도
|
RU2644263C2
(ru)
|
2012-06-27 |
2018-02-08 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
KR101774121B1
(ko)
|
2012-07-13 |
2017-09-01 |
로슈 글리카트 아게 |
이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
US9279016B2
(en)
|
2012-09-19 |
2016-03-08 |
Abbvie Biotherapeutics Inc. |
Methods for identifying antibodies with reduced immunogenicity
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
BR112015006521B1
(pt)
|
2012-10-11 |
2022-03-03 |
Daiichi Sankyo Company, Limited |
Conjugado anticorpo-fármaco, seu método de preparação e seu uso, fármacos e composição farmacêutica
|
ES2782248T3
(es)
|
2012-10-19 |
2020-09-11 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
|
CA2889756C
(en)
|
2012-10-26 |
2023-03-14 |
Memorial Sloan-Kettering Cancer Center |
Thiohydantoin compounds as androgen receptor modulators
|
DK2914627T3
(da)
|
2012-10-30 |
2021-07-12 |
Apexigen Inc |
Anti-cd40-antistoffer og fremgangsmåder til anvendelse
|
JP6694712B2
(ja)
|
2012-11-01 |
2020-05-20 |
マックス−デルブルック−セントラム フアー モレキュラーレ メデジン |
Cd269(bcma)に対する抗体
|
KR102167228B1
(ko)
|
2012-11-05 |
2020-10-19 |
피에르 파브르 메디카먼트 |
새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도
|
WO2014072481A1
(en)
|
2012-11-08 |
2014-05-15 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
PE20150945A1
(es)
|
2012-11-13 |
2015-06-26 |
Genentech Inc |
Anticuerpos de antihemaglutinina y metodos de uso
|
CN105849086B
(zh)
|
2012-11-24 |
2018-07-31 |
杭州多禧生物科技有限公司 |
亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
JP6334553B2
(ja)
|
2012-12-10 |
2018-05-30 |
メルサナ セラピューティクス,インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
BR112015018418A2
(pt)
|
2013-02-22 |
2017-07-18 |
Hoffmann La Roche |
métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
MX2015011428A
(es)
|
2013-03-06 |
2016-02-03 |
Genentech Inc |
Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US20140328849A1
(en)
|
2013-03-15 |
2014-11-06 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
BR112015023084A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
MX368665B
(es)
|
2013-03-15 |
2019-10-10 |
Abbvie Biotherapeutics Inc |
Variantes de fc.
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
CA2905798C
(en)
|
2013-03-15 |
2023-01-24 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
ES2743216T3
(es)
|
2013-03-15 |
2020-02-18 |
Xencor Inc |
Proteínas heterodiméricas
|
KR102233349B1
(ko)
|
2013-03-15 |
2021-03-31 |
에이씨 이뮨 에스.에이. |
항-타우(tau) 항체 및 사용 방법
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2014179657A1
(en)
|
2013-05-03 |
2014-11-06 |
Eleven Biotherapeutics, Inc. |
Albumin variants binding to fcrn
|
MX2015015970A
(es)
|
2013-05-20 |
2016-09-08 |
Genentech Inc |
Anticuerpos receptores de antitransferina y metodos de uso.
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
KR20160060634A
(ko)
|
2013-08-01 |
2016-05-30 |
어젠시스 인코포레이티드 |
Cd37 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
AU2014331909B2
(en)
|
2013-10-10 |
2020-03-12 |
Beth Israel Deaconess Medical Center, Inc. |
TM4SF1 binding proteins and methods of using same
|
LT3055331T
(lt)
|
2013-10-11 |
2021-03-25 |
Oxford Bio Therapeutics Limited |
Konjuguoti antikūnai prieš ly75, skirti vėžio gydymui
|
BR112016007736B1
(pt)
|
2013-10-11 |
2022-09-27 |
Mersana Therapeutics, Inc |
Armação polimérica, e, composição farmacêutica
|
AU2014331645C1
(en)
|
2013-10-11 |
2020-06-11 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
AR098221A1
(es)
*
|
2013-11-04 |
2016-05-18 |
Pfizer |
Conjugados de anticuerpo anti-efna4-fármaco
|
MX371011B
(es)
*
|
2013-11-04 |
2020-01-13 |
Pfizer |
Intermediarios y métodos para sintetizar derivados de calicheamicina.
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
EP3082875B1
(en)
|
2013-12-16 |
2020-11-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
CA2934524C
(en)
|
2013-12-23 |
2022-02-15 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for treating cancer using peptide nucleic acid-based agents
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
BR112016014945A2
(pt)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugado, formulação farmacêutica e uso
|
CA2933384A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
KR102278979B1
(ko)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2935393A1
(en)
|
2014-01-24 |
2015-07-30 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
RU2685728C2
(ru)
|
2014-01-29 |
2019-04-23 |
Шанхай Хэнжуй Фармасьютикал Ко., Лтд. |
Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
US9518121B2
(en)
|
2014-02-12 |
2016-12-13 |
Genentech, Inc. |
Anti-Jagged1 antibodies and methods of use
|
EA201691473A1
(ru)
|
2014-02-21 |
2016-12-30 |
Дженентек, Инк. |
Биспецифические анти-il-13/il-17 антитела и их применение
|
CN106414465B
(zh)
|
2014-02-28 |
2021-11-16 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
SI3116999T1
(sl)
|
2014-03-14 |
2021-12-31 |
F. Hoffmann - La Roche Ag |
Postopki in sestavki za izločanje heterolognih polipeptidov
|
SG11201607746QA
(en)
|
2014-03-21 |
2016-10-28 |
Abbvie Inc |
Anti-egfr antibodies and antibody drug conjugates
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
TWI797430B
(zh)
|
2014-03-27 |
2023-04-01 |
中央研究院 |
反應性標記化合物及其用途
|
AP2016009475A0
(en)
|
2014-03-28 |
2016-09-30 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
AU2015243377A1
(en)
|
2014-04-11 |
2016-09-15 |
Medimmune, Llc |
Bispecific HER2 antibodies
|
MA39378B2
(fr)
|
2014-04-25 |
2021-02-26 |
Pf Medicament |
Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
|
SG10201809628SA
(en)
|
2014-04-30 |
2018-11-29 |
Pfizer |
Anti-ptk7 antibody-drug conjugates
|
HRP20231139T1
(hr)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗her2醣抗體及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CN107074945B
(zh)
|
2014-05-27 |
2021-08-24 |
中央研究院 |
增进抗体功效的通用糖型的组合物及方法
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
CN106687476B
(zh)
|
2014-06-26 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
抗brdu抗体及使用方法
|
US9914774B2
(en)
|
2014-07-11 |
2018-03-13 |
Genentech, Inc. |
Notch pathway inhibition
|
US20160060360A1
(en)
|
2014-07-24 |
2016-03-03 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
ES2913865T3
(es)
|
2014-08-28 |
2022-06-06 |
Bioatla Inc |
Receptores de antígeno quimérico condicionalmente activos para células T modificadas
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
CA2957354A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
US20170304460A1
(en)
|
2014-10-01 |
2017-10-26 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
JP6723509B2
(ja)
|
2014-10-24 |
2020-07-15 |
日油株式会社 |
環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
|
WO2016070062A2
(en)
|
2014-10-31 |
2016-05-06 |
Genentech, Inc. |
Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
CN107108740B
(zh)
|
2014-11-05 |
2021-09-17 |
豪夫迈·罗氏有限公司 |
抗fgfr2/3抗体及其使用方法
|
CA2960797A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
CR20170240A
(es)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
ES2886523T3
(es)
|
2014-11-26 |
2021-12-20 |
Xencor Inc |
Anticuerpos heterodiméricos que se unen a CD3 y CD20
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
CR20170230A
(es)
|
2014-12-05 |
2017-11-07 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
PL3233910T3
(pl)
|
2014-12-19 |
2020-06-01 |
Ablynx N.V. |
Dimery nanociał połączone cysteiną
|
MY183415A
(en)
|
2014-12-19 |
2021-02-18 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
CN107428833B
(zh)
|
2015-01-16 |
2021-11-02 |
朱诺治疗学股份有限公司 |
Ror1特异性抗体和嵌合抗原受体
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
GB201501004D0
(en)
|
2015-01-21 |
2015-03-04 |
Cancer Rec Tech Ltd |
Inhibitors
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
KR102630294B1
(ko)
|
2015-01-24 |
2024-01-26 |
아카데미아 시니카 |
암 마커 및 이를 사용하는 방법
|
EP3789766A1
(en)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
US10441649B2
(en)
|
2015-02-02 |
2019-10-15 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3253778A1
(en)
|
2015-02-05 |
2017-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
CA2983158A1
(en)
*
|
2015-04-21 |
2016-10-27 |
Abbvie Stemcentrx Llc |
Calicheamicin constructs and methods of use
|
CN115932273A
(zh)
|
2015-04-24 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
JP6952605B2
(ja)
|
2015-04-24 |
2021-10-20 |
ジェネンテック, インコーポレイテッド |
多特異性抗原結合タンパク質
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
US20160346387A1
(en)
|
2015-05-11 |
2016-12-01 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体を使用して癌を治療する方法
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
RU2748943C2
(ru)
|
2015-06-16 |
2021-06-02 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
JP2018524312A
(ja)
|
2015-06-17 |
2018-08-30 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び使用方法
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
BR112017027736A2
(pt)
|
2015-06-29 |
2018-10-09 |
Genentech Inc |
anticorpo anti-cd20 tipo ii para uso no transplante de órgãos
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
KR20180030917A
(ko)
|
2015-08-05 |
2018-03-26 |
얀센 바이오테크 인코포레이티드 |
항-cd154 항체 및 그의 사용 방법
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
BR112018003179A2
(pt)
|
2015-08-20 |
2018-09-25 |
Albumedix As |
conjugados e variantes de albumina
|
IL257565B1
(en)
|
2015-09-23 |
2024-04-01 |
Genentech Inc |
Improved variants of anti-VEGF antibodies
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
US10017572B2
(en)
|
2015-09-25 |
2018-07-10 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
CA3000400A1
(en)
|
2015-09-30 |
2017-04-06 |
Janssen Biotech, Inc. |
Agonistic antibodies specifically binding human cd40 and methods of use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
MY190297A
(en)
|
2015-10-02 |
2022-04-12 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
EP4036120A1
(en)
|
2015-10-30 |
2022-08-03 |
F. Hoffmann-La Roche AG |
Hinge modified antibody fragments and methods of making
|
MX2018005550A
(es)
|
2015-11-03 |
2019-07-18 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a tim-3 y sus usos.
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
CN112807429A
(zh)
|
2015-11-19 |
2021-05-18 |
雷维托普有限公司 |
用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
|
WO2017095823A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
PE20240365A1
(es)
|
2015-12-18 |
2024-03-04 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
BR112018015259A2
(pt)
|
2016-01-27 |
2018-12-18 |
Medimmune Llc |
métodos para preparação de anticorpos com um padrão de glicosilação definido
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
EP3411076B1
(en)
|
2016-02-05 |
2021-04-28 |
Rigshospitalet |
Antibody-drug conjugates targeting uparap
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US11340233B2
(en)
|
2016-03-07 |
2022-05-24 |
Pierre Fabre Medicament |
Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
WO2017172907A1
(en)
*
|
2016-03-29 |
2017-10-05 |
Sorrento Therapeutics, Inc. |
Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
WO2017180842A1
(en)
|
2016-04-15 |
2017-10-19 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
SG11201808979UA
(en)
|
2016-04-15 |
2018-11-29 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
EP3889175A1
(en)
|
2016-05-02 |
2021-10-06 |
F. Hoffmann-La Roche AG |
The contorsbody - a single chain target binder
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
EP3455252B1
(en)
|
2016-05-11 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Modified anti-tenascin antibodies and methods of use
|
PT3455261T
(pt)
|
2016-05-13 |
2022-11-11 |
Bioatla Llc |
Anticorpos anti-ror2, fragmentos de anticorpo, seus imunoconjugados e suas utilizações
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
WO2017207540A1
(en)
|
2016-05-30 |
2017-12-07 |
Toxinvent Oü |
Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
EP3468997B1
(en)
|
2016-06-08 |
2023-09-13 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
BR112018075626A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco anticorpo
|
JP2019521973A
(ja)
|
2016-06-08 |
2019-08-08 |
アッヴィ・インコーポレイテッド |
抗bh7−h3抗体及び抗体薬物コンジュゲート
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
AU2017277916A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
EP3482205A1
(en)
|
2016-07-08 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
|
JP7062640B2
(ja)
|
2016-07-29 |
2022-05-06 |
ジュノー セラピューティクス インコーポレイテッド |
抗cd19抗体に対する抗イディオタイプ抗体
|
WO2018026533A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
JP2018058822A
(ja)
|
2016-08-03 |
2018-04-12 |
ファイザー・インク |
ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
EP3504239B1
(en)
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
EP3526241A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Il15/il15r heterodimeric fc-fusion proteins
|
KR102617264B1
(ko)
|
2016-10-19 |
2023-12-29 |
인벤라 인코포레이티드 |
항체 구조물
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
KR102532256B1
(ko)
|
2016-11-21 |
2023-05-12 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
EP3559038B1
(en)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
WO2018115485A1
(en)
|
2016-12-22 |
2018-06-28 |
Pierfrancesco Tassone |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
US11993625B2
(en)
|
2017-01-24 |
2024-05-28 |
Pfizer, Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
KR20200003843A
(ko)
|
2017-04-27 |
2020-01-10 |
테사로, 인코포레이티드 |
림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
CN111315414A
(zh)
|
2017-06-22 |
2020-06-19 |
梅尔莎纳医疗公司 |
产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法
|
CA3067603A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
US20190048073A1
(en)
|
2017-07-20 |
2019-02-14 |
Pfizer Inc. |
Anti-gd3 antibodies and antibody-drug conjugates
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3699590A4
(en)
|
2017-10-20 |
2021-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
MOLECULE INTERNALIZATION MEASUREMENT PROCESS IN A CELL
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
CN111278856A
(zh)
|
2017-11-01 |
2020-06-12 |
豪夫迈·罗氏有限公司 |
三Fab-康特斯体
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
PE20211116A1
(es)
|
2018-02-08 |
2021-06-23 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso
|
EP3759141A1
(en)
|
2018-02-26 |
2021-01-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
SG11202008796VA
(en)
|
2018-03-14 |
2020-10-29 |
The United States Of America As Represented By The Secretary |
Anti-cd33 chimeric antigen receptors and their uses
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
SG11202011309SA
(en)
|
2018-05-14 |
2020-12-30 |
Werewolf Therapeutics Inc |
Activatable interleukin 12 polypeptides and methods of use thereof
|
AU2019271148B2
(en)
|
2018-05-14 |
2023-07-06 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
WO2019234136A1
(en)
|
2018-06-05 |
2019-12-12 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
CR20210047A
(es)
|
2018-07-02 |
2021-05-21 |
Amgen Inc |
Proteína de unión al antígeno anti-steap1
|
CA3105694A1
(en)
|
2018-07-12 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
CN112739340A
(zh)
|
2018-07-23 |
2021-04-30 |
美真达治疗公司 |
抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
|
WO2020033430A1
(en)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
JP6718560B1
(ja)
|
2018-08-10 |
2020-07-08 |
中外製薬株式会社 |
抗cd137抗原結合分子およびその使用
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
MX2021005398A
(es)
|
2018-11-07 |
2021-07-06 |
Crispr Therapeutics Ag |
Terapia del cancer con celulas inmunitarias anti-cd33.
|
EP3883610A4
(en)
|
2018-11-20 |
2022-11-02 |
Cornell University |
MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
WO2020127968A1
(en)
|
2018-12-20 |
2020-06-25 |
Marino Stephen F |
Protein-drug conjugate comprising a monomeric form of proteinase 3
|
EP3902832A2
(en)
|
2018-12-26 |
2021-11-03 |
Xilio Development, Inc. |
Anti-ctla4 antibodies and methods of use thereof
|
CA3125484A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
CN113329763A
(zh)
|
2019-01-22 |
2021-08-31 |
豪夫迈·罗氏有限公司 |
免疫球蛋白a抗体以及制备和使用方法
|
EP3883971A1
(en)
|
2019-01-22 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
JP2022529154A
(ja)
|
2019-04-19 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗mertk抗体及びその使用方法
|
MX2021012767A
(es)
|
2019-04-19 |
2021-11-18 |
Janssen Biotech Inc |
Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
|
AU2020265679A1
(en)
|
2019-04-30 |
2021-12-23 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
CN114450022A
(zh)
|
2019-05-14 |
2022-05-06 |
狼人治疗公司 |
分离部分及其使用方法
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20230002481A1
(en)
|
2019-05-15 |
2023-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
An antigen-binding molecule, a pharmaceutical composition, and a method
|
MX2021014932A
(es)
|
2019-06-03 |
2022-04-06 |
Univ Chicago |
Métodos y composiciones para tratar cáncer con portadores de fármacos que se enlazan al colágeno.
|
WO2020248065A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Ontario Institute For Cancer Research (Oicr) |
Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
US20230121556A1
(en)
|
2019-06-17 |
2023-04-20 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
KR20220033493A
(ko)
|
2019-07-10 |
2022-03-16 |
추가이 세이야쿠 가부시키가이샤 |
클로딘 6 결합 분자 및 그의 사용
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
AU2020330133A1
(en)
|
2019-08-14 |
2022-03-17 |
Lonza Sales Ag |
Extracellular vesicle-ASO constructs targeting CEBP/beta
|
US20230193274A1
(en)
|
2019-08-14 |
2023-06-22 |
Codiak Biosciences, Inc. |
Extracellular vesicles with stat3-antisense oligonucleotides
|
CA3147680A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting stat6
|
CN114829586A
(zh)
|
2019-08-14 |
2022-07-29 |
科迪亚克生物科学公司 |
细胞外囊泡-nlrp3拮抗剂
|
KR20220088847A
(ko)
|
2019-09-04 |
2022-06-28 |
주식회사 와이바이오로직스 |
항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
WO2021066869A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
EP4031250A1
(en)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
AU2020378330A1
(en)
|
2019-11-06 |
2022-05-12 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
EP4247957A1
(en)
|
2019-11-22 |
2023-09-27 |
MedImmune Limited |
Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
IL293430A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Anti-idiotic antibodies to bcma-targeted binding domains and related compositions and methods
|
WO2021118968A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
IL293423A
(en)
|
2019-12-13 |
2022-07-01 |
Genentech Inc |
Anti-ly6g6d antibodies and methods of use
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2021148003A1
(zh)
|
2020-01-22 |
2021-07-29 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
BR112022018657A2
(pt)
|
2020-03-19 |
2022-11-01 |
Genentech Inc |
Anticorpos, ácido nucleico, célula hospedeira, imunoconjugado, formulação farmacêutica, usos de um anticorpo, métodos de produção de um anticorpo e de tratamento de um indivíduo, métodos para inibir a sinalização de smad e para diagnosticar um indivíduo como tendo ssc e kit
|
JP2023521956A
(ja)
|
2020-03-25 |
2023-05-26 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体の調製方法
|
CA3175733A1
(en)
|
2020-03-25 |
2021-09-30 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Pharmaceutical composition comprising antibody drug conjugate and use thereof
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
CA3175530A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
US20230220068A1
(en)
|
2020-06-05 |
2023-07-13 |
Codiak Biosciences, Inc. |
Anti-transferrin extracellular vesicles
|
CA3183808A1
(en)
|
2020-06-11 |
2021-12-16 |
Genentech, Inc. |
Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
JP2023531200A
(ja)
|
2020-06-18 |
2023-07-21 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療
|
TW202204895A
(zh)
|
2020-07-13 |
2022-02-01 |
美商建南德克公司 |
預測多肽免疫性的基於細胞之方法
|
US20230296612A1
(en)
|
2020-07-29 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring pharmacokinetics of agent labeled with non-radioactive substance
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
KR20230042596A
(ko)
|
2020-08-07 |
2023-03-28 |
제넨테크, 인크. |
Flt3 리간드 융합 단백질 및 이용 방법
|
JP2023537683A
(ja)
|
2020-08-07 |
2023-09-05 |
ジェネンテック, インコーポレイテッド |
ポリペプチド免疫原性を予測するためのt細胞ベースの方法
|
WO2022056490A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
EP4236970A1
(en)
|
2020-10-27 |
2023-09-06 |
Vor Biopharma Inc. |
Compositions and methods for treating hematopoietic malignancy
|
JP7402381B2
(ja)
|
2020-11-04 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
TW202225191A
(zh)
|
2020-11-04 |
2022-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
BR112023015097A2
(pt)
|
2021-01-28 |
2023-10-03 |
Janssen Biotech Inc |
Proteínas de ligação a psma e usos das mesmas
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
KR20230156727A
(ko)
|
2021-03-03 |
2023-11-14 |
피에르 파브르 메디카먼트 |
항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
KR20240037188A
(ko)
|
2021-04-30 |
2024-03-21 |
피에르 파브르 메디카먼트 |
신규의 안정한 항-vista 항체
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
JPWO2022244838A1
(ja)
|
2021-05-19 |
2022-11-24 |
|
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
AR126054A1
(es)
|
2021-06-04 |
2023-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-ddr2 y usos de estos
|
AU2022291120A1
(en)
|
2021-06-09 |
2023-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
CA3221833A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody
|
EP4361176A1
(en)
|
2021-06-25 |
2024-05-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
KR20240046524A
(ko)
|
2021-08-07 |
2024-04-09 |
제넨테크, 인크. |
미만성 거대 b-세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
|
AU2022327766A1
(en)
|
2021-08-13 |
2023-12-14 |
Ludwig-Maximilians-Universität München |
Anti-csf1r car expressing lymphocytes for targeted tumor therapy
|
PE20240727A1
(es)
|
2021-08-27 |
2024-04-15 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
TW202323810A
(zh)
|
2021-10-08 |
2023-06-16 |
日商中外製藥股份有限公司 |
預填充式注射器製劑的調製方法
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022404647A1
(en)
|
2021-12-08 |
2024-06-13 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
DK4314031T3
(da)
|
2022-02-15 |
2024-06-17 |
Tagworks Pharmaceuticals B V |
Maskeret il12-protein
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
TW202408562A
(zh)
|
2022-04-13 |
2024-03-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
WO2023215293A1
(en)
|
2022-05-02 |
2023-11-09 |
Athanor Biosciences, Inc. |
Cancer eradicating – bio-nanoparticles (ce-bnp)
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024073751A1
(en)
|
2022-09-29 |
2024-04-04 |
Vor Biopharma Inc. |
Methods and compositions for gene modification and enrichment
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024089013A1
(en)
|
2022-10-25 |
2024-05-02 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|